The German Society of Amyloid Diseases and the German Neurological Society have issued an expert consensus establishing second-generation gene silencers as the preferred first-line treatment for most patients with symptomatic hereditary transthyretin amyloidosis with polyneuropathy in Germany. Hereditary transthyretin amyloidosis is a rare, progressive multisystem disorder caused by pathogenic variants in the transthyretin gene, leading to protein misfolding, aggregation, and extracellular deposition of amyloid fibrils. In patients presenting with polyneuropathy, amyloid deposition results in a length-dependent sensorimotor and autonomic neuropathy frequently accompanied by cardiomyopathy. Without intervention, the disease leads to rapid clinical deterioration, irreversible loss of neurological function, substantial morbidity, and premature mortality. Across clinical trials, disease-modifying therapies have significantly slowed progression and improved patient survival and quality of life compared with placebo. However, because lost neurological function cannot be retrieved, early diagnosis and prompt treatment initiation remain critical.
Published as an official position statement in Neurological Research and Practice, the recommendations were developed by a multidisciplinary panel appointed jointly by the two German medical societies. The authors conducted a structured literature search of the PubMed database spanning January 1980 through March 2026, combining search terms such as hereditary transthyretin amyloidosis, transthyretin, polyneuropathy, therapy, stabilizer, and silencer, supplemented by manual screening of relevant reference lists. Eligible studies evaluated approved therapies and emerging gene-editing approaches, prioritizing randomized controlled clinical trials, prospective cohorts, and high-quality observational investigations while excluding non-English publications and studies lacking methodological transparency. Because of substantial heterogeneity across trial designs, populations, endpoints, and follow-up durations, the authors did not perform a formal meta-analysis. Instead, evidence was synthesized narratively with explicit consideration of cross-trial limitations. The resulting recommendations integrate clinical trial evidence with regulatory evaluations and early benefit assessments from the German Federal Joint Committee.
Under the consensus guidance, disease-modifying therapy should be initiated as early as possible in symptomatic patients carrying confirmed amyloidogenic transthyretin variants, with marketing authorizations in Germany not requiring biopsy confirmation of amyloid deposition. Conversely, for asymptomatic variant carriers, there is currently no approved therapy to prevent clinical disease onset. Asymptomatic carriers with histologically documented amyloid deposits who lack clinical manifestations require rigorous longitudinal monitoring and multidisciplinary board evaluation. Therapeutic indications are defined according to Coutinho disease stages. Under this classification, stage 1 designates fully ambulatory patients; stage 2 comprises individuals who require walking aids; and stage 3 defines patients who are wheelchair-bound or bedridden. All six disease-modifying agents authorized in the European Union are approved for stage 1 polyneuropathy. In stage 2, the oral stabilizer tafamidis is not authorized, whereas the remaining five disease-modifying therapies retain regulatory approval.
Evaluating published clinical evidence, safety profiles, and treatment burdens, the expert panel recommends initiating first-line therapy with one of two second-generation ribonucleic acid silencers: the small interfering RNA vutrisiran or the antisense oligonucleotide eplontersen. Both agents target hepatic transthyretin synthesis, providing profound reductions in circulating protein levels, favorable adverse-effect profiles, and convenient subcutaneous delivery schedules that facilitate outpatient care. Vutrisiran is administered by subcutaneous injection every three months, whereas eplontersen is injected subcutaneously once monthly using an autoinjector designed for home self-administration. Although statistical modeling from a recent meta-analysis supports these second-generation agents, the panel emphasizes that direct head-to-head clinical trials comparing vutrisiran with eplontersen are lacking. Regulatory evaluations by the German Federal Joint Committee indicate that neither drug can be considered superior in overall efficacy. However, eplontersen has demonstrated documented efficacy in autonomic neuropathy, whereas vutrisiran has established approval in cardiomyopathy, for which eplontersen trials remain ongoing.
First-generation gene-silencing therapeutics, including patisiran and inotersen, are designated as second-line treatment options due to administrative burdens and safety considerations. Patisiran demonstrated considerable additional benefit in early regulatory evaluations, but its requirement for intravenous infusions every three weeks accompanied by corticosteroid premedication imposes a substantial long-term treatment burden. Inotersen provides weekly subcutaneous self-injection, but its additional benefit was classified as not quantifiable by regulatory authorities, and it requires strict laboratory monitoring due to risks of thrombocytopenia and renal toxicities. For patients who explicitly prefer oral administration over subcutaneous injections, tafamidis represents the primary alternative. Data from clinical trials and real-world registries indicate that patients in early stage 1 carrying the specific p.(Val50Met) variant, particularly female patients, achieve responder rates of approximately 70 percent under tafamidis with minimal side effects. Nevertheless, the panel positions tafamidis primarily as a bridging therapy, emphasizing that patients showing disease progression must be switched immediately to a silencer.
Alternative oral stabilizing agents include diflunisal, a non-steroidal anti-inflammatory drug that stabilizes transthyretin tetramers and may offer efficacy comparable to tafamidis, but its utility is constrained by risks of gastrointestinal, renal, and cardiac toxicity. Another stabilizer, acoramidis, provides potent binding across thyroxine-binding sites but has not been studied in polyneuropathy and is approved exclusively for cardiomyopathy. In routine clinical monitoring, the panel defines disease progression as any worsening or emergence of disease-specific signs or symptoms, advising clinicians to apply combinations of standardized tests rather than a single score. If polyneuropathy progresses during stabilizer treatment, immediate transition to a second-generation silencer is recommended. If progression occurs under a silencer, serum prealbumin levels should be assessed to verify suppression efficiency. While combining a silencer with a stabilizer could theoretically stabilize residual circulating tetramers at low concentrations, evidence remains inconclusive, and substantial costs mandate that combination regimens be reserved for refractory cases evaluated by multidisciplinary boards.
For patients progressing to Coutinho stage 3 who become non-ambulatory, therapeutic management presents notable ethical and clinical challenges, as none of the approved disease-modifying agents has been systematically investigated in trials focusing specifically on bedridden or wheelchair-bound cohorts. The panel explicitly recommends continuing gene-silencing treatment in patients who lose ambulation while already receiving therapy, noting that withdrawing treatment solely because a patient has progressed to stage 3 is ethically questionable. Recognizing that securing health insurance reimbursement for advanced stage 3 care can involve lengthy administrative negotiations, the authors urge clinicians to discuss individual cases within specialized multidisciplinary amyloidosis boards and to evaluate these advanced disease outcomes within ongoing clinical research registries.
Musculoskeletal manifestations frequently precede the clinical onset of systemic hereditary transthyretin amyloidosis by years or decades, serving as crucial diagnostic red flags. Pathological amyloid deposition in connective tissues commonly manifests as bilateral carpal tunnel syndrome, lumbar spinal stenosis, or spontaneous tendon ruptures, particularly involving the biceps tendon. While these orthopedic presentations can mimic neuropathic symptoms, no approved treatments exist to prevent subsequent systemic development. The panel advises that patients with confirmed transthyretin amyloid in soft-tissue biopsies undergo genetic testing alongside neurological and cardiological examinations. Because cardiac involvement significantly drives overall morbidity and mortality through restrictive cardiomyopathy, ventricular thickening, diastolic dysfunction, and severe conduction disorders, regular cardiological follow-up is essential. For cardiomyopathy, approved treatments include tafamidis at a 61-milligram dose, acoramidis, and vutrisiran. In patients with wild-type transthyretin amyloid cardiomyopathy where polyneuropathy is increasingly recognized, disease-modifying therapies directed at myocardial amyloid deposition are mechanistically expected to stabilize peripheral nerve structures as well.
Amyloid deposition in ocular tissues presents further management considerations, as vitreous opacities, glaucoma, conjunctival vascular abnormalities, and retinal changes can progress despite systemic therapy, occasionally necessitating vitreoretinal surgery. Concurrently, central nervous system involvement is becoming an increasingly prominent clinical challenge as improved peripheral therapeutics extend patient life expectancy. Specific transthyretin variants predispose individuals to leptomeningeal amyloidosis, progressive cognitive decline, seizures, cerebral microbleeds, and intracranial hemorrhages. Following orthotopic liver transplantation, approximately 30 percent of patients carrying the p.(Val50Met) variant develop central nervous system manifestations within 15 years, demonstrating that synthesis in the choroid plexus persists independently of hepatic targeted therapies. Currently approved disease-modifying drugs cannot cross the blood-brain barrier in therapeutic concentrations, preventing direct central nervous system toxicities while leaving intracranial amyloid formation unaddressed. Tolcapone represents an off-label candidate capable of crossing into cerebrospinal fluid to stabilize tetramers, though it requires multiple daily doses and vigilant hepatic monitoring.
Within the German statutory healthcare system, practical administration and regulatory considerations heavily influence disease-modifying treatment decisions. Because gene-silencing agents reduce circulating transthyretin levels and secondary retinol transport, patients receiving silencers require regular daily vitamin A supplementation, an expense generally not reimbursed by statutory health insurance in Germany. In post-transplant populations experiencing disease progression driven by wild-type amyloid deposition on pre-existing fibrils, dedicated phase 3b trial evidence supports patisiran as an effective, well-tolerated therapy without allograft rejection, while observational data offer limited support for inotersen and tafamidis under careful hepatic oversight. Given the extraordinary acquisition costs associated with orphan therapies, the German reimbursement framework designates these agents as special practice practices, shielding prescribing specialists in certified amyloidosis centers from individual budgetary liabilities while requiring transparent documentation of diagnostic indications, Coutinho stages, and longitudinal treatment responses.
Looking toward future therapeutic horizons, novel disease-modifying strategies promise to further expand options for hereditary transthyretin amyloidosis. Early-phase clinical investigations evaluating in vivo CRISPR-Cas9 gene editing directed at hepatic transthyretin synthesis have demonstrated durable protein knockdown following single administration, raising prospects for one-time curative interventions. Simultaneously, amyloid-depleting monoclonal antibodies such as PRX004 and NI006 are undergoing phase 3 clinical evaluation to actively clear established extracellular amyloid fibrils from affected tissues. Third-generation ribonucleic acid interference agents, including nucresiran evaluated in the TRITON-PN and TRITON-CM trial programs, seek to extend therapeutic suppression across neurological and cardiac manifestations. In addition, presymptomatic intervention is gaining momentum through the ACT-EARLY phase 3 trial, which investigates prophylactic administration of acoramidis in asymptomatic variant carriers to prevent disease onset. Together, these advancing modalities reflect a paradigm shift toward earlier intervention and targeted fibril clearance, complementing the established expert consensus framework guiding current clinical practice in Germany.
Subject of Research: Expert consensus recommendations on disease-modifying therapies for hereditary transthyretin amyloidosis with polyneuropathy in Germany
Article Title: Disease modifying treatment of hereditary transthyretin amyloidosis with polyneuropathy in Germany – expert consensus of the German society of amyloid diseases (DGAK) and the German neurological society (DGN)
Article References: Weiler, M., Dohrn, M. F., Gingele, S., Skripuletz, T., Schilling, M., Hagenacker, T., Hund, E., Sachau, J., Baron, R., Pernice, H., Spethmann, S., Khandanpour, C., Carpinteiro, A., Morbach, C., & Hahn, K. (2026). Disease modifying treatment of hereditary transthyretin amyloidosis with polyneuropathy in Germany – expert consensus of the German society of amyloid diseases (DGAK) and the German neurological society (DGN). Neurological Research and Practice, 8(1), Article 63. https://doi.org/10.1186/s42466-026-00521-4
Image Credits: AI Generated
DOI: 10.1186/s42466-026-00521-4
Keywords: hereditary transthyretin amyloidosis, polyneuropathy, gene silencers, transthyretin stabilizers, vutrisiran, eplontersen, tafamidis, patisiran, inotersen, diflunisal, German Society of Amyloid Diseases, German Neurological Society, Coutinho disease stages, cardiomyopathy, central nervous system amyloidosis, orthotopic liver transplantation
News Source: Juliet Wilcox. (November 19, 2026). German Consensus Recommends Second-Generation Gene Silencers for Hereditary Transthyretin Polyneuropathy. Scienmag.



